Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Line Clear all
Not yet recruiting No phase listed Observational

Central Line-Associated Bloodstream Infection QI Project

NCT07746674
View directory record Official record
Conditions
Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 3 Interventional

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

NCT04869943
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Simulation-based Training for Surgery Residents in Aseptic Techniques

NCT00787345
View directory record Official record
Conditions
Nosocomial Infections
Interventions
simulation based training
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 30, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

NCT06669572
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Anorectal Cancer
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

NCT01084330
View directory record Official record
Conditions
Advanced Gastric Cancer, Gastro-esophageal Junction Cancer
Interventions
AUY922, Docetaxel, Irinotecan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Lafayette, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 30, 2026, 4:45 PM EDT
Available No phase listed Expanded access

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

NCT04513821
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
Mino-Lok Therapy (MLT)
Drug
Lead sponsor
Leonard-Meron Biosciences, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
27
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00005093
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, tacedinaline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 30, 2026, 4:45 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

NCT01263574
View directory record Official record
Conditions
Catheter Related Infections, Short Bowel Syndrome
Interventions
70% ethanol
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 30, 2026, 4:45 PM EDT
Not yet recruiting No phase listed Observational

Duke Virtual IntEgrated Workflow

NCT07406074
View directory record Official record
Conditions
Falls Injury, Readmission Rates, CLABSI - Central Line Associated Bloodstream Infection, Catheter Associated Urinary Tract Infection, Hospital Acquired Pressure Injury, Venous Thromboembolism (VTE), Nurses, Satisfaction, Patient, Length of Stay
Interventions
Co-Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

NCT00006488
View directory record Official record
Conditions
Parkinson Disease
Interventions
recombinant-methionyl human glial cell line-derived neurotrophic factor
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional Results available

Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer

NCT00633061
View directory record Official record
Conditions
Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection, Catheter-related Occlusion
Interventions
Enoxaparin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 4:45 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558
View directory record Official record
Conditions
Ovarian Neoplasms, Ovarian Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
27
States / cities
Birmingham, Alabama • Walnut Creek, California • Miami Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

NCT05879484
View directory record Official record
Conditions
Sinonasal Cancer, Squamous Non-small Cell Lung Cancer, Lung Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcnimona, Head and Neck Cancer
Interventions
pembrolizumab, valemetostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Point of Care Ultrasound for PICC Line Monitoring Study

NCT03954977
View directory record Official record
Conditions
Peripherally Inserted Central Catheters
Interventions
PICC line ultrasound
Diagnostic Test
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 12 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 30, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sunitinib and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

NCT00710333
View directory record Official record
Conditions
Keloid
Interventions
Avotermin, placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional

Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids

NCT00836147
View directory record Official record
Conditions
Keloid
Interventions
Avotermin (Juvista), Placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Oct 30, 2026, 4:45 PM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Peripherally Inserted Versus Centrally Inserted Central Venous Catheters in the Neurological Intensive Care

NCT01495429
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Central venous catheter
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 30, 2026, 4:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT07355205
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 4:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Simulation Training for Ultrasound Guided Central Venous Catheter Insertion

NCT00919308
View directory record Official record
Conditions
Procedural Skill Competency
Interventions
Competency based simulation training
Other
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 30, 2026, 4:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT02655016
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
47
States / cities
Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 30, 2026, 4:45 PM EDT